CANY
STRO icon

Caxton Associates (New York)’s Sutro Biopharma STRO Stock Holding History

Caxton Associates (New York)’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,135
Closed -$99.3K – 584
2023
Q2 		$99.3K Sell
2,135
-762
-26% -$37.9K 0.01% 451
2023
Q1 		$134K Sell
2,897
-4,827
-62% -$306K 0.02% 447
2022
Q4 		$624K Hold
7,724
– – 0.04% 197
2022
Q3 		$429K Buy
7,724
+3,570
+86% +$211K 0.06% 269
2022
Q2 		$216K Buy
+4,154
New +$232K 0.02% 455

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Caxton Associates (New York)'s STRO Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Sutro Biopharma (STRO) in Q3 2023, closing a stake of 2,135 shares — an estimated $99.3K sold.

Caxton Associates (New York) first reported a position in STRO in Q2 2022 and held it in 5 quarters. The position peaked at $624K in Q4 2022. 108 funds tracked by Wall St. Rank hold STRO as of Q3 2023.

  • Caxton Associates (New York) reported no remaining Sutro Biopharma position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 2,135 Sutro Biopharma shares in Q3 2023, an estimated $99.3K.
  • Caxton Associates (New York) first reported a position in Sutro Biopharma in Q2 2022 and held it in 5 quarters.
  • Caxton Associates (New York)'s Sutro Biopharma position peaked at $624K in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.